Aurinia Pharmaceuticals (AUPH) Earnings Date, Estimates & Call Transcripts $12.08 -0.03 (-0.25%) Closing price 04:00 PM EasternExtended Trading$11.99 -0.09 (-0.74%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aurinia Pharmaceuticals Earnings Summary Aurinia Pharmaceuticals released Q2 2025 earnings on July 31, 2025, reporting an EPS of $0.16, which missed analysts' consensus estimates of $0.17 by $0.01. Quarterly revenue was reported to be $70.01 million, above analysts' expectations of $64.27 million. With a trailing EPS of $0.43 and a P/E Ratio of 28.09, Aurinia Pharmaceuticals' earnings are expected to grow 409.09% next year, from $0.11 to $0.56 per share. Upcoming Q3 Earnings DateNov. 6Before Market OpensEstimatedConsensus EPS (Jul. 31) $0.17 Actual EPS (Jul. 31) $0.16 Missed By -$0.01 Actual Revenue (Jul. 31) $70.01MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)SEC FilingAUPH Upcoming EarningsAurinia Pharmaceuticals' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules. Powered by Get Aurinia Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataAUPH Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AUPH Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Aurinia Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251$0.10$0.10$0.10Q2 20252$0.16$0.16$0.16Q3 20252$0.15$0.18$0.17Q4 20252$0.16$0.19$0.18 FY 2025 7 $0.57 $0.63 $0.60 Q1 20262$0.15$0.18$0.17Q2 20262$0.17$0.18$0.18Q3 20262$0.16$0.18$0.17Q4 20262$0.14$0.18$0.16 Aurinia Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/6/2025(Estimated)--------7/31/2025Q2 2025$0.17$0.16 -$0.01$0.16$64.27M$70.01M5/12/2025Q1 2025$0.08$0.16+$0.08$0.16$61.06M$62.47M8/1/2024Q2 2024$0.01$0.01-$0.03$54.25M$57.10M5/2/2024Q1 2024-$0.17-$0.03+$0.14$0.01$46.30M$50.30M2/15/2024Q4 2023-$0.16-$0.19 -$0.03-$0.19$45.00M$45.10M11/2/2023Q3 2023-$0.17-$0.09+$0.08-$0.09$38.41M$54.52M Aurinia Pharmaceuticals Earnings - Frequently Asked Questions When is Aurinia Pharmaceuticals' earnings date? Aurinia Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based off last year's report dates. Learn more on AUPH's earnings history. What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings? Aurinia Pharmaceuticals issued an update on its FY 2025 earnings guidance on Thursday, July, 31st. The company issued revenue guidance of $260.0 million-$270.0 million, compared to the consensus revenue estimate of $258.5 million. Did Aurinia Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) missed the analysts' consensus estimate of $0.17 by $0.01 with a reported earnings per share (EPS) of $0.16. Learn more on analysts' earnings estimate vs. AUPH's actual earnings. How can I listen to Aurinia Pharmaceuticals' earnings conference call? The conference call for Aurinia Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read Aurinia Pharmaceuticals' conference call transcript? The conference call transcript for Aurinia Pharmaceuticals' latest earnings report can be read online. Read Transcript How can I view Aurinia Pharmaceuticals' earnings report? Aurinia Pharmaceuticals' earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Aurinia Pharmaceuticals generate each year? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a recorded annual revenue of $235.13 million. How much profit does Aurinia Pharmaceuticals generate each year? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a recorded net income of $5.75 million. AUPH has generated $0.43 earnings per share over the last four quarters. What is Aurinia Pharmaceuticals' price-to-earnings ratio? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a trailing price-to-earnings ratio of 28.09 and a forward price-to-earnings ratio of 109.82. What is Aurinia Pharmaceuticals' EPS forecast for next year? Aurinia Pharmaceuticals' earnings are expected to grow from $0.11 per share to $0.56 per share in the next year, which is a 409.09% increase. More Earnings Resources from MarketBeat Related Companies LEGN Earnings Results RNA Earnings Results AXSM Earnings Results NUVL Earnings Results MRUS Earnings Results CRSP Earnings Results TGTX Earnings Results CYTK Earnings Results ACAD Earnings Results KRYS Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost Pressures This page (NASDAQ:AUPH) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access